ABSTRACT
C1-inhibitor (C1-inh) is a crucial regulator of the activation of plasmatic cascade systems involved in inflammation contributing to the homeostasis in the generation of proinflammatory mediators. The importance of C1-inh is illustrated by patients with hereditary angioedema where decreased levels of C1-inh lead to an uncontrolled generation of vasoactive peptides resulting in potential life-threatening subcutaneous edema. Recent publications, however, suggest that the anti-inflammatory properties of C1-inh do not strictly depend on its capacity to regulate the complement and contact phase system. This review summarizes the biochemical characteristics of C1-inh and its role in the regulation of plasmatic cascade systems as well as the role of the nonserpin domain.
KEYWORDS
C1-inhibitor - hereditary angioedema - serpin - contact phase - complement - sepsis
REFERENCES
1
Caliezi C, Wuillemin W A, Zeerleder S, Redondo M, Eisele B, Hack C E.
C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema.
Pharmacol Rev.
2000;
52
(1)
91-112
2
Schapira M, de Agostini A, Schifferli J A, Colman R W.
Biochemistry and pathophysiology of human C1 inhibitor: current issues.
Complement.
1985;
2
(2–3)
111-126
3
Nuijens J H, Eerenberg-Belmer A JM, Huijbregts C C et al..
Proteolytic inactivation of plasma C1-inhibitor in sepsis.
J Clin Invest.
1989;
84
(2)
443-450
4
Travis J, Salvesen G S.
Human plasma proteinase inhibitors.
Annu Rev Biochem.
1983;
52
655-709
5 Carrell R W, Boswell D R. Serpins: the superfamily of plasma proteinase inhibitors. In: Barrett A J, Salvesen G, eds. Proteinase Inhibitors. Amsterdam, The Netherlands: Elsevier; 1990: 403-420
6
Carrell R W, Travis J.
α1-antitrypsin and the serpins: variation and countervariation.
Trends Biochem Sci.
1985;
10
20-24
7
Carter P E, Dunbar B, Fothergill J E.
Genomic and cDNA cloning of the human C1 inhibitor. Intron-exon junctions and comparison with other serpins.
Eur J Biochem.
1988;
173
(1)
163-169
8
Coutinho M, Aulak K S, Davis III A E.
Functional analysis of the serpin domain of C1 inhibitor.
J Immunol.
1994;
153
(8)
3648-3654
9
Wagenaar-Bos I G, Hack C E.
Structure and function of C1-inhibitor.
Immunol Allergy Clin North Am.
2006;
26
(4)
615-632
10
Bock S C, Skriver K, Nielsen E et al..
Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization.
Biochemistry.
1986;
25
(15)
4292-4301
11
Bos I G, Lubbers Y T, Roem D, Abrahams J P, Hack C E, Eldering E.
The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant.
J Biol Chem.
2003;
278
(32)
29463-29470
12
Huntington J A, Read R J, Carrell R W.
Structure of a serpin-protease complex shows inhibition by deformation.
Nature.
2000;
407
(6806)
923-926
13
Schapira M, de Agostini A, Colman R W.
C1 inhibitor: the predominant inhibitor of plasma kallikrein.
Methods Enzymol.
1988;
163
179-185
14
Ravindran S, Grys T E, Welch R A, Schapira M, Patston P A.
Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor.
Thromb Haemost.
2004;
92
(6)
1277-1283
15
Minta J O.
The role of sialic acid in the functional activity and the hepatic clearance of C1-INH.
J Immunol.
1981;
126
(1)
245-249
16
Reboul A, Prandini M H, Colomb M G.
Proteolysis and deglycosylation of human C1 inhibitor. Effect on functional properties.
Biochem J.
1987;
244
(1)
117-121
17
van Doorn M B, Burggraaf J, van Dam T et al..
A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema.
J Allergy Clin Immunol.
2005;
116
(4)
876-883
18
Bos I G, de Bruin E C, Karuntu Y A, Modderman P W, Eldering E, Hack C E.
Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor.
Biochim Biophys Acta.
2003;
1648
(1–2)
75-83
19
Bensa J C, Reboul A, Colomb M G.
Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes.
Biochem J.
1983;
216
(2)
385-392
20
Yeung Laiwah A C, Jones L, Hamilton A O, Whaley K.
Complement-subcomponent-C1-inhibitor synthesis by human monocytes.
Biochem J.
1985;
226
(1)
199-205
21
Katz Y, Strunk R C.
Synthesis and regulation of C1 inhibitor in human skin fibroblasts.
J Immunol.
1989;
142
(6)
2041-2045
22
Katz Y, Gur S, Aladjem M, Strunk R C.
Synthesis of complement proteins in amnion.
J Clin Endocrinol Metab.
1995;
80
(7)
2027-2032
23
Walker D G, Yasuhara O, Patston P A, McGeer E G, McGeer P L.
Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease.
Brain Res.
1995;
675
(1–2)
75-82
24
Lotz M, Zuraw B L.
Interferon-gamma is a major regulator of C1-inhibitor synthesis by human blood monocytes.
J Immunol.
1987;
139
(10)
3382-3387
25
Zuraw B L, Lotz M.
Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte stimulating factors interleukin 6 and interferon gamma.
J Biol Chem.
1990;
265
(21)
12664-12670
26
Schmidt B, Gyapay G, Válay M, Füst G.
Human recombinant macrophage colony-stimulating factor (M-CSF) increases Cl-esterase inhibitor (Cl-INH) synthesis by human monocytes.
Immunology.
1991;
74
(4)
677-679
27
Heda G D, Mardente S, Weiner L, Schmaier A H.
Interferon γ increases in vitro and in vivo expression of C1 inhibitor.
Blood.
1990;
75
(12)
2401-2407
28
Heda G D, Kehoe K J, Mahdi F, Schmaier A H.
Phosphatase 2A participates in interferon-γ's induced upregulation of C1 inhibitor mRNA expression.
Blood.
1996;
87
(7)
2831-2838
29
Zahedi K, Prada A E, Prada J A, Davis III A E.
Characterization of the IFN-γ-responsive element in the 5′ flanking region of the C1 inhibitor gene.
J Immunol.
1997;
159
(12)
6091-6096
30
Schmaier A H, Amenta S, Xiong T, Heda G D, Gewirtz A M.
Expression of platelet C1 inhibitor.
Blood.
1993;
82
(2)
465-474
31
Woo P, Lachmann P JL, Harrison R A, Amos N, Cooper C, Rosen F S.
Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases.
Clin Exp Immunol.
1985;
61
(1)
1-8
32
Quastel M, Harrison R, Cicardi M, Alper C A, Rosen F S.
Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema.
J Clin Invest.
1983;
71
(4)
1041-1046
33
de Smet BJGL, de Boer J P, Agterberg J, Rigter G, Bleeker W K, Hack C E.
Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats.
Blood.
1993;
81
(1)
56-61
34
Pappalardo E, Zingale L C, Cicardi M.
C1 inhibitor gene expression in patients with hereditary angioedema: quantitative evaluation by means of real-time RT-PCR.
J Allergy Clin Immunol.
2004;
114
(3)
638-644
35
Wuillemin W A, Bleeker W K, Agterberg J, Rigter G, ten Cate H, Hack C E.
Clearance of human factor XIa-inhibitor complexes in rats.
Br J Haematol.
1996;
93
(4)
950-954
36
Nuijens J H, Huijbregts C C, Eerenberg-Belmer A JM et al..
Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis.
Blood.
1988;
72
(6)
1841-1848
37
Perlmutter D H, Glover G I, Rivetna M, Schasteen C S, Fallon R J.
Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes.
Proc Natl Acad Sci U S A.
1990;
87
(10)
3753-3757
38
Pizzo S V, Mast A E, Feldman S R, Salvesen G.
In vivo catabolism of α 1-antichymotrypsin is mediated by the Serpin receptor which binds α 1-proteinase inhibitor, antithrombin III and heparin cofactor II.
Biochim Biophys Acta.
1988;
967
(2)
158-162
39
Kalter E S, Daha M R, ten Cate J W, Verhoef J, Bouma B N.
Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock.
J Infect Dis.
1985;
151
(6)
1019-1027
40
Falus A, Rokita H, Walcz E, Brozik M, Hidvégi T, Merétey K.
Hormonal regulation of complement biosynthesis in human cell lines—II. Upregulation of the biosynthesis of complement components C3, factor B and C1 inhibitor by interleukin-6 and interleukin-1 in human hepatoma cell line.
Mol Immunol.
1990;
27
(2)
197-201
41
Brower M S, Harpel P C.
Proteolytic cleavage and inactivation of α 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.
J Biol Chem.
1982;
257
(16)
9849-9854
42
Eldering E, Huijbregts C CM, Nuijens J H, Verhoeven A J, Hack C E.
Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.
J Clin Invest.
1993;
91
(3)
1035-1043
43
Leid R W, Ballieux BEPB, van der Heijden I et al..
Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3.
Eur J Immunol.
1993;
23
(11)
2939-2944
44
Wallace E M, Perkins S J, Sim R B, Willis A C, Feighery C, Jackson J.
Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes.
Mol Med.
1997;
3
(6)
385-396
45
Catanese J, Kress L F.
Enzymatic inactivation of human plasma C1-inhibitor and α 1-antichymotrypsin by Pseudomonas aeruginosa proteinase and elastase.
Biochim Biophys Acta.
1984;
789
(1)
37-43
46
Zhang F, Bries A D, Lang S C et al..
Metabolic alteration of the N-glycan structure of a protein from patients with a heterozygous protein deficiency.
Biochim Biophys Acta.
2004;
1739
(1)
43-49
47
Doekes G, van Es L A, Daha M R.
C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
Immunology.
1983;
49
(2)
215-222
48
Tenner A J, Frank M M.
Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1.
J Immunol.
1986;
137
(2)
625-630
49
Turner M W.
Mannose-binding lectin: the pluripotent molecule of the innate immune system.
Immunol Today.
1996;
17
(11)
532-540
50
Thiel S, Vorup-Jensen T, Stover C M et al..
A second serine protease associated with mannan-binding lectin that activates complement.
Nature.
1997;
386
(6624)
506-510
51
Matsushita M, Fujita T.
Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease.
J Exp Med.
1992;
176
(6)
1497-1502
52
Matsushita M, Thiel S, Jensenius J C, Terai I, Fujita T.
Proteolytic activities of two types of mannose-binding lectin-associated serine protease.
J Immunol.
2000;
165
(5)
2637-2642
53
Makrides S C.
Therapeutic inhibition of the complement system.
Pharmacol Rev.
1998;
50
(1)
59-87
54
Podack E R, Kolb W P, Müller-Eberhard H J.
The SC5b-7 complex: formation, isolation, properties, and subunit composition.
J Immunol.
1977;
119
(6)
2024-2029
55
Tschopp J, Müller-Eberhard H J, Podack E R.
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9.
Nature.
1982;
298
(5874)
534-538
56
Hugli T E, Müller-Eberhard H J.
Anaphylatoxins: C3a and C5a.
Adv Immunol.
1978;
26
1-53
57
Morgan E L.
Modulation of the immune response by anaphylatoxins.
Complement.
1986;
3
(3)
128-136
58
Hartmann K, Henz B M, Krüger-Krasagakes S et al..
C3a and C5a stimulate chemotaxis of human mast cells.
Blood.
1997;
89
(8)
2863-2870
59
Gerard C, Gerard N P.
C5A anaphylatoxin and its seven transmembrane-segment receptor.
Annu Rev Immunol.
1994;
12
775-808
60
Sim R B, Reboul A, Arlaud G J, Villiers C L, Colomb M G.
Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma.
FEBS Lett.
1979;
97
(1)
111-115
61
Liszewski M K, Farries T C, Lublin D M, Rooney I A, Atkinson J P.
Control of the complement system.
Adv Immunol.
1996;
61
201-283
62
Bianchino A C, Poon P H, Schumaker V N.
A mechanism for the spontaneous activation of the first component of complement, C1, and its regulation by C1-inhibitor.
J Immunol.
1988;
141
(11)
3930-3936
63
Harpel P C, Cooper N R.
Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.
J Clin Invest.
1975;
55
(3)
593-604
64
Reboul A, Arlaud G J, Sim R B, Colomb M G.
A simplified procedure for the purification of C1-inactivator from human plasma. Interaction with complement subcomponents C1r and C1s.
FEBS Lett.
1977;
79
(1)
45-50
65
Salvesen G S, Catanese J J, Kress L F, Travis J.
Primary structure of the reactive site of human C1-inhibitor.
J Biol Chem.
1985;
260
(4)
2432-2436
66
Arlaud G J, Reboul A, Sim R B, Colomb M G.
Interaction of C1-inhibitor with the C1r and C1s subcomponents in human C1.
Biochim Biophys Acta.
1979;
576
(1)
151-162
67
Ziccardi R J, Cooper N R.
Active disassembly of the first complement component, C-1, by C-1 inactivator.
J Immunol.
1979;
123
(2)
788-792
68
Chesne S, Villiers C L, Arlaud G J, Lacroix M B, Colomb M G.
Fluid-phase interaction of C1 inhibitor (C1 Inh) and the subcomponents C1r and C1s of the first component of complement, C1.
Biochem J.
1982;
201
(1)
61-70
69
Sim R B, Arlaud G J, Colomb M G.
Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s.
Biochim Biophys Acta.
1980;
612
(2)
433-449
70
Jiang H, Wagner E, Zhang H, Frank M M.
Complement 1 inhibitor is a regulator of the alternative complement pathway.
J Exp Med.
2001;
194
(11)
1609-1616
71
Kaplan A P, Silverberg M.
The coagulation-kinin pathway of human plasma.
Blood.
1987;
70
(1)
1-15
72
Colman R W.
Surface-mediated defense reactions. The plasma contact activation system.
J Clin Invest.
1984;
73
(5)
1249-1253
73
Cochrane C G, Griffin J H.
The biochemistry and pathophysiology of the contact system of plasma.
Adv Immunol.
1982;
33
241-306
74
Hojima Y, Cochrane C G, Wiggins R C, Austen K F, Stevens R L.
In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E.
Blood.
1984;
63
(6)
1453-1459
75
Kannemeier C, Shibamiya A, Nakazawa F et al..
Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation.
Proc Natl Acad Sci U S A.
2007;
104
(15)
6388-6393
76
Maas C, Govers-Riemslag J W, Bouma B et al..
Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.
J Clin Invest.
2008;
118
(9)
3208-3218
77
Müller F, Mutch N J, Schenk W A et al..
Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.
Cell.
2009;
139
(6)
1143-1156
78
Herwald H, Mörgelin M, Olsén A et al..
Activation of the contact-phase system on bacterial surfaces—a clue to serious complications in infectious diseases.
Nat Med.
1998;
4
(3)
298-302
79
Colman R W, Bagdasarian A, Talamo R C et al..
Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways.
J Clin Invest.
1975;
56
(6)
1650-1662
80
Ghebrehiwet B, Randazzo B P, Dunn J T, Silverberg M, Kaplan A P.
Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.
J Clin Invest.
1983;
71
(5)
1450-1456
81
Schousboe I.
Binding of activated factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor.
Eur J Biochem.
2003;
270
(1)
111-118
82
Lämmle B, Wuillemin W A, Huber I et al..
Thromboembolism and bleeding tendency in congenital factor XII deficiency—a study on 74 subjects from 14 Swiss families.
Thromb Haemost.
1991;
65
(2)
117-121
83
Pixley R A, De La Cadena R, Page J D et al..
The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons.
J Clin Invest.
1993;
91
(1)
61-68
84
Gailani D, Broze Jr G J.
Factor XI activation in a revised model of blood coagulation.
Science.
1991;
253
(5022)
909-912
85
Naito K, Fujikawa K.
Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces.
J Biol Chem.
1991;
266
(12)
7353-7358
86
Renné T, Pozgajová M, Grüner S et al..
Defective thrombus formation in mice lacking coagulation factor XII.
J Exp Med.
2005;
202
(2)
271-281
87
Wuillemin W A, Minnema M, Meijers J C et al..
Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor.
Blood.
1995;
85
(6)
1517-1526
88
Wuillemin W A, Hack C E, Bleeker W K, Biemond B J, Levi M, ten Cate H.
Inactivation of factor Xia in vivo: studies in chimpanzees and in humans.
Thromb Haemost.
1996;
76
(4)
549-555
89
Nielsen E W, Morrissey J, Olsen J O, Osterud B.
Factor VIIa in patients with C1-inhibitor deficiency.
Thromb Haemost.
1995;
74
(4)
1103-1106
90
Nielsen E W, Johansen H T, Høgåsen K, Wuillemin W A, Hack C E, Mollnes T E.
Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema.
Scand J Immunol.
1996;
44
(2)
185-192
91
Husain S S, Hasan A AK, Budzynski A Z.
Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots.
Blood.
1989;
74
(3)
999-1006
92
Vassalli J D, Sappino A P, Belin D.
The plasminogen activator/plasmin system.
J Clin Invest.
1991;
88
(4)
1067-1072
93
Zamarron C, Lijnen H R, Van Hoef B, Collen D.
Biological and thrombolytic properties of proenzyme and active forms of human urokinase—I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
Thromb Haemost.
1984;
52
(1)
19-23
94
Schmaier A H.
Contact activation: a revision.
Thromb Haemost.
1997;
78
(1)
101-107
95
Schousboe I.
Factor XIIa activation of plasminogen is enhanced by contact activating surfaces and Zn2+.
Blood Coagul Fibrinolysis.
1997;
8
(2)
97-104
96
Levi M, Hack C E, de Boer J P, Brandjes D P, Büller H R, ten Cate J W.
Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo.
J Clin Invest.
1991;
88
(4)
1155-1160
97
Zeerleder S, Schloesser M, Redondo M et al..
Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency—a study on 73 subjects from 14 Swiss families.
Thromb Haemost.
1999;
82
(4)
1240-1246
98
Huisman L GM, van Griensven J MT, Kluft C.
On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma.
Thromb Haemost.
1995;
73
(3)
466-471
99
Levi M, Roem D, Kamp A M, de Boer J P, Hack C E, ten Cate J W.
Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.
Thromb Haemost.
1993;
69
(2)
141-146
100
Römisch J, Feussner A, Vermöhlen S, Stöhr H A.
A protease isolated from human plasma activating factor VII independent of tissue factor.
Blood Coagul Fibrinolysis.
1999;
10
(8)
471-479
101
Römisch J, Vermöhlen S, Feussner A, Stöhr H.
The FVII activating protease cleaves single-chain plasminogen activators.
Haemostasis.
1999;
29
(5)
292-299
102
Etscheid M, Hunfeld A, König H, Seitz R, Dodt J.
Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism.
Biol Chem.
2000;
381
(12)
1223-1231
103
Muhl L, Galuska S P, Oörni K et al..
High negative charge-to-size ratio in polyphosphates and heparin regulates factor VII-activating protease.
FEBS J.
2009;
276
(17)
4828-4839
104
Nakazawa F, Kannemeier C, Shibamiya A et al..
Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP).
Biochem J.
2005;
385
(Pt 3)
831-838
105
Yamamichi S, Nishitani M, Nishimura N, Matsushita Y, Hasumi K.
Polyamine-promoted autoactivation of plasma hyaluronan-binding protein.
J Thromb Haemost.
2010;
8
(3)
559-566
106
Kannemeier C, Feussner A, Stöhr H A, Weisse J, Preissner K T, Römisch J.
Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme.
Eur J Biochem.
2001;
268
(13)
3789-3796
107
Etscheid M, Beer N, Fink E, Seitz R, Johannes D.
The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin.
Biol Chem.
2002;
383
(10)
1633-1643
108
Zeerleder S, Zwart B, te Velthuis H et al..
A plasma nucleosome releasing factor (NRF) with serine protease activity is instrumental in removal of nucleosomes from secondary necrotic cells.
FEBS Lett.
2007;
581
(28)
5382-5388
109
Zeerleder S, Zwart B, te Velthuis H et al..
Nucleosome-releasing factor: a new role for factor VII-activating protease (FSAP).
FASEB J.
2008;
22
(12)
4077-4084
110
Kannemeier C, Al-Fakhri N, Preissner K T, Kanse S M.
Factor VII-activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells.
FASEB J.
2004;
18
(6)
728-730
111
Sedding D, Daniel J M, Muhl L et al..
The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation.
J Exp Med.
2006;
203
(13)
2801-2807
112
Choi-Miura N H, Takahashi K, Yoda M, Saito K, Mazda T, Tomita M.
Proteolytic activation and inactivation of the serine protease activity of plasma hyaluronan binding protein.
Biol Pharm Bull.
2001;
24
(5)
448-452
113
Potempa J, Korzus E, Travis J.
The serpin superfamily of proteinase inhibitors: structure, function, and regulation.
J Biol Chem.
1994;
269
(23)
15957-15960
114
Caughman G B, Boackle R J, Vesely J.
A postulated mechanism for heparin's potentiation of C1 inhibitor function.
Mol Immunol.
1982;
19
(2)
287-295
115
Lennick M, Brew S A, Ingham K C.
Kinetics of interaction of C1 inhibitor with complement C1s.
Biochemistry.
1986;
25
(13)
3890-3898
116
Nilsson T, Wiman B.
Kinetics of the reaction between human C1-esterase inhibitor and C1r or C1s.
Eur J Biochem.
1983;
129
(3)
663-667
117
Pixley R A, Schmaier A, Colman R W.
Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor.
Arch Biochem Biophys.
1987;
256
(2)
490-498
118
Rent R, Myhrman R, Fiedel B A, Gewurz H.
Potentiation of C1 esterase inhibitor activity by heparin.
Clin Exp Immunol.
1976;
23
264-271
119
Wuillemin W A, te Velthuis H, Lubbers Y T, de Ruig C P, Eldering E, Hack C E.
Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma.
J Immunol.
1997;
159
(4)
1953-1960
120
Bos I G, van Mierlo G J, Bleeker W K et al..
The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model.
Int Immunopharmacol.
2001;
1
(8)
1583-1595
121
Caldwell E E, Andreasen A M, Blietz M A et al..
Heparin binding and augmentation of C1 inhibitor activity.
Arch Biochem Biophys.
1999;
361
(2)
215-222
122
Wuillemin W A, Eldering E, Citarella F, de Ruig C P, ten Cate H, Hack C E.
Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa.
J Biol Chem.
1996;
271
(22)
12913-12918
123
Mauron T, Lämmle B, Wuillemin W A.
Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins.
Thromb Haemost.
1998;
80
(1)
82-86
124
Zeerleder S, Caliezi C, van Mierlo G et al..
Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis.
Clin Diagn Lab Immunol.
2003;
10
(4)
529-535
125
Jansen P M, Eisele B, de Jong I W et al..
Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock.
J Immunol.
1998;
160
(1)
475-484
126
Caliezi C, Zeerleder S, Redondo M et al..
C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction.
Crit Care Med.
2002;
30
(8)
1722-1728
127
Cai S, Dole V S, Bergmeier W et al..
A direct role for C1 inhibitor in regulation of leukocyte adhesion.
J Immunol.
2005;
174
(10)
6462-6466
128
Liu D, Cai S, Gu X, Scafidi J, Wu X, Davis III A E.
C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide.
J Immunol.
2003;
171
(5)
2594-2601
129
Liu D, Lu F, Qin G, Fernandes S M, Li J, Davis III A E.
C1 inhibitor-mediated protection from sepsis.
J Immunol.
2007;
179
(6)
3966-3972
130
Zhang H, Li J, Barrington R A, Liang G, Qin G, Liu D X.
An anti-endotoxin peptide that generates from the amino-terminal domain of complement regulatory protein C1 inhibitor.
Biochem Biophys Res Commun.
2007;
359
(2)
285-291
131
Liu D, Gu X, Scafidi J, Davis III A E.
N-linked glycosylation is required for c1 inhibitor-mediated protection from endotoxin shock in mice.
Infect Immun.
2004;
72
(4)
1946-1955
132
Liu D, Cramer C C, Scafidi J, Davis III A E.
N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A.
Infect Immun.
2005;
73
(8)
4478-4487
133
Liu D, Zhang D, Scafidi J, Wu X, Cramer C C, Davis III A E.
C1 inhibitor prevents gram-negative bacterial lipopolysaccharide-induced vascular permeability.
Blood.
2005;
105
(6)
2350-2355
134
Horstick G, Heimann A, Götze O et al..
Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion.
Circulation.
1997;
95
(3)
701-708
135
de Zwaan C, Kleine A H, Diris J H et al..
Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction.
Eur Heart J.
2002;
23
(21)
1670-1677
136
Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S.
C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor.
Expert Opin Biol Ther.
2008;
8
(8)
1225-1240
137
Cichon S, Martin L, Hennies H C et al..
Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III.
Am J Hum Genet.
2006;
79
(6)
1098-1104
138
Bork K, Schneiders V.
Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema.
J Hepatol.
2002;
36
(5)
707-709
139
Cugno M, Nuijens J, Hack E et al..
Plasma levels of C1-inhibitor complexes and cleaved C1-inhibitor in patients with hereditary angioneurotic edema.
J Clin Invest.
1990;
85
(4)
1215-1220
140
Davis III A E.
The pathophysiology of hereditary angioedema.
Clin Immunol.
2005;
114
(1)
3-9
141
Noga O, Brunnée T, Schäper C, Kunkel G.
Heparin, derived from the mast cells of human lungs, is responsible for the generation of kinins in allergic reactions due to the activation of the contact system.
Int Arch Allergy Immunol.
1999;
120
(4)
310-316
142
Brunnée T, Reddigari S R, Shibayama Y, Kaplan A P, Silverberg M.
Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions.
Clin Exp Allergy.
1997;
27
(6)
653-663
143
Iwaki T, Castellino F J.
Plasma levels of bradykinin are suppressed in factor XII-deficient mice.
Thromb Haemost.
2006;
95
(6)
1003-1010
144
Shariat-Madar Z, Mahdi F, Schmaier A H.
Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator.
J Biol Chem.
2002;
277
(20)
17962-17969
145
Bork K, Siedlecki K, Bosch S, Schopf R E, Kreuz W.
Asphyxiation by laryngeal edema in patients with hereditary angioedema.
Mayo Clin Proc.
2000;
75
(4)
349-354
146
Bork K, Barnstedt S E.
Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema.
Arch Intern Med.
2001;
161
(5)
714-718
147
Bork K, Meng G, Staubach P, Hardt J.
Hereditary angioedema: new findings concerning symptoms, affected organs, and course.
Am J Med.
2006;
119
(3)
267-274
148
Castro-Magana M, Cheruvanky T, Collipp P J, Ghavami-Maibodi Z, Angulo M, Stewart C.
Transient adrenogenital syndrome due to exposure to danazol in utero.
Am J Dis Child.
1981;
135
(11)
1032-1034
149
Agostoni A, Bergamaschini L, Martignoni G, Cicardi M, Marasini B.
Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate.
Ann Allergy.
1980;
44
(5)
299-301
150
Agostoni A, Cicardi M.
Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients.
Medicine (Baltimore).
1992;
71
(4)
206-215
151
Bork K, Witzke G.
Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency.
J Allergy Clin Immunol.
1989;
83
(3)
677-682
152
Cicardi M, Bergamaschini L, Marasini B, Boccassini G, Tucci A, Agostoni A.
Hereditary angioedema: an appraisal of 104 cases.
Am J Med Sci.
1982;
284
(1)
2-9
153
Waytes A T, Rosen F S, Frank M M.
Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate.
N Engl J Med.
1996;
334
(25)
1630-1634
154
Prematta M, Gibbs J G, Pratt E L, Stoughton T R, Craig T J.
Fresh frozen plasma for the treatment of hereditary angioedema.
Ann Allergy Asthma Immunol.
2007;
98
(4)
383-388
155
Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W.
Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant).
J Allergy Clin Immunol.
2007;
119
(6)
1497-1503
156
Kunschak M, Engl W, Maritsch F et al..
A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema.
Transfusion.
1998;
38
(6)
540-549
157
Bork K, Meng G, Staubach P, Hardt J.
Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema.
Transfusion.
2005;
45
(11)
1774-1784
158
Zuraw B L, Busse P J, White M et al..
Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema.
N Engl J Med.
2010;
363
(6)
513-522
159
Craig T J, Levy R J, Wasserman R L et al..
Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.
J Allergy Clin Immunol.
2009;
124
(4)
801-808
160
Choi G, Soeters M R, Farkas H et al..
Recombinant human C1-inhibitor in the treatment of acute angioedema attacks.
Transfusion.
2007;
47
(6)
1028-1032
161
Zuraw B, Cicardi M, Levy R J, Nuijens J H et al..
Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema.
J Allergy Clin Immunol.
2010;
126
(4)
821-827
Sacha ZeerlederM.D. Ph.D.
Department of Immunopathology, Sanquin Research, Plesmanlaan 125
1066 CX Amsterdam, The Netherlands
Email: s.zeerleder@sanquin.nl